Pharmacotherapy of Alzheimer's disease: Current and future trends

Expert Review of Neurotherapeutics

Volumn 15, Issue 1, 2014, Pages 3-5

  Geldenhuys, Werner J ^a   Darvesh, Altaf S ^a,b  

^a NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

^b Northeast Ohio Medical University   (United States)

Author keywords

Alzheimer's disease; anti inflammatory agents; antioxidants; cholinesterase inhibitors; dementia; immunotherapy; memantine; multi targeted drugs; natural products; Pharmacotherapy

Indexed keywords

5,6 DIHYDRO 2 IMINO 3 METHYL 6 [4 [5 (1 PROPYNYL) 3 PYRIDINYL] 2 THIENYL] 4 PYRIMIDINONE; ALPHA TOCOPHEROL; ANTIINFLAMMATORY AGENT; ASCORBIC ACID; BAPINEUZUMAB; CALCIUM CHANNEL BLOCKING AGENT; CATECHIN; CRENEZUMAB; CURCUMIN; DICLOFENAC; DONEPEZIL; GALANTAMINE; GANTENERUMAB; MEMANTINE; METHYLENE BLUE; NAPROXEN; NATURAL PRODUCT; NOOTROPIC AGENT; OMEGA 3 FATTY ACID; PHYTOESTROGEN; RESVERATROL; RIVASTIGMINE; ROFECOXIB; SELENIUM; SOLANEZUMAB; TACRINE; THIOCTIC ACID; UBIDECARENONE;

ACTIVE IMMUNIZATION; ALZHEIMER DISEASE; AMYLOID PLAQUE; ANTIOXIDANT ACTIVITY; BLOOD ANALYSIS; CELL LOSS; CEREBROSPINAL FLUID; CHOLINERGIC ACTIVITY; CHOLINERGIC SYNAPSE; CLINICAL TRIAL (TOPIC); COGNITIVE DEFECT; DEGENERATIVE DISEASE; DEMENTIA; DISEASE COURSE; DRUG INDUSTRY; DRUG SAFETY; DRUG TARGETING; EXCITOTOXICITY; GINKGO BILOBA; HUMAN; IMMUNOTHERAPY; INFLAMMATION; MENTAL DETERIORATION; META ANALYSIS (TOPIC); NERVOUS SYSTEM INFLAMMATION; NEUROFIBRILLARY TANGLE; NONHUMAN; OXIDATIVE STRESS; PASSIVE IMMUNIZATION; PATHOGENESIS; PHARMACEUTICAL CARE; PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN INTERACTION; REVIEW; PROCEDURES; TRENDS;

ALZHEIMER DISEASE; DRUG THERAPY; HUMANS;

EID: 84920792929     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.2015.990884     Document Type: Review

References (20)

1. Thies W, Bleiler L. Alzheimer's Association. 2013 Alzheimer's disease facts and figures. Alzheimer's Dement 2013;9:208-45
2. Karran E, Merckan M, De Strooper B. The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov 2011;10:698-712
3. Carreiras MC, Mendes E, Perry MJ, et al. The multifactorial nature of Alzheimer's disease for developing potential therapeutics. Curr Topics Med Chem 2013;13:1745-70
4. Francis PT, Palmer AM, Snape M, et al. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J Neurol Neurosurg Psychiatry 1999;66:137-47
5. Tan CC, Yu JT, Wang HF, et al. Efficacy and safety of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease: a systematic review and meta-analysis. J Alzheimer's Dis 2014;41:615-31
6. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev 2006;1:CD005593
7. Broadstock M, Ballard C, Corbett A. Latest treatment options for Alzheimer's disease, Parkinson's disease dementia and dementia with Lewy bodies. Expert Opin Pharmacother 2014;15:1797-810
8. Yan R, Vassar R. Targeting the b secretase BACE1 for Alzheimer's disease therapy. Lancet Neurol 2014;13:319-29
9. Lannfelt L, Relkin NR, Siemers ER. Amyloid b directed immunotherapy for Alzheimer's disease. J Int Med 2014;275: 284-95
10. Lambracht-Washington D, Rosenberg RN. Anti-amyloid beta to tau-based immunization: developments in immunotherapy for Alzheimer disease. Immunotargets Ther 2013;2:105-14
11. Persson T, Popescu BO, Cedazo-Minguez A. Oxidative stress in Alzhemier's disease: Why did antioxidant therapy fail Oxid Med Cell Long 2014;2014:427318
12. Zhou W, Hu W. Anti-neuroinflammatory agents for the treatment of Alzheimer's disease. Future Med Chem 2013;5:1559-71
13. Morales I, Guzmán-Martinez L, Cerda-Troncoso C, et al. Neuroinflammation in the pathogenesis of Alzheimer's disease. A rational framework for the search of novel therapeutic approaches. Front Cell Neurosci 2014;8:112
14. Crichton GE, Bryan J, Murphy KJ. Dietary antioxidants, cognitive function and dementia- A systematic review. Plant Foods Hum Nutr 2013;68:279-92
15. Darvesh AS, Carroll RT, Geldenhuys WJ, et al. Oxidative stress and Alzheimer's disease: dietary polyphenols as potential therapeutic agents. Expert Rev Neurother 2010;10:729-45
16. Soni M, Rahardjo TB, Soekardi R, et al. Phytoestrogens and cognitive function: a review. Maturitas 2014;77:209-20
17. Yang M, Xu DD, Zhang Y, et al. A systematic review on natural medicines for the prevention and treatment of Alzheimer's disease with meta-analysis of intervention effect of ginkgo. Amer J Chinese Med 2014;42:505-21
18. Froestl W, Muhs A, Pfeifer A. Cognitive enhancers (Nootropics). Part 1: drugs interacting with receptors. J Alzheimer's Dis 2014;41:961-1019
19. Froestl W, Muhs A, Pfeifer A. Cognitive enhancers (Nootropics). Part 2: drugs interacting with enzymes. J Alzheimer's Dis 2013;33:547-658
20. Bajda M, Guzior N, Ignasik M. Multi-target-directed ligands in Alzheimer's treatment. Curr Med Chem 2011;18: 4949-75